Bavarian Nordic Stock Price, News & Analysis (OTCMKTS:BVNRY)

$13.66 +0.26 (+1.94 %)
(As of 02/20/2018 02:22 AM ET)
Previous Close$13.40
Today's Range$13.66 - $13.66
52-Week Range$11.06 - $22.70
Volume700 shs
Average Volume883 shs
Market Capitalization$1.31 billion
P/E Ratio18.46
Dividend YieldN/A
Beta-1.72

About Bavarian Nordic (OTCMKTS:BVNRY)

Bavarian Nordic logoBavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen’s AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1). The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Receive BVNRY News and Ratings via Email

Sign-up to receive the latest news and ratings for BVNRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:BVNRY
CUSIPN/A
Phone45-3326-8383

Debt

Debt-to-Equity Ratio0.01%
Current Ratio10.27%
Quick Ratio9.89%

Price-To-Earnings

Trailing P/E Ratio18.4594594594595
Forward P/E Ratio27.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$149.68 million
Price / Sales8.76
Cash Flow$0.12 per share
Price / Cash113.83
Book Value$3.19 per share
Price / Book4.28

Profitability

Trailing EPS$0.74
Net Income$4.54 million
Net Margins26.62%
Return on Equity21.19%
Return on Assets16.04%

Miscellaneous

Employees437
Outstanding Shares96,040,000

Bavarian Nordic (OTCMKTS:BVNRY) Frequently Asked Questions

What is Bavarian Nordic's stock symbol?

Bavarian Nordic trades on the OTCMKTS under the ticker symbol "BVNRY."

When will Bavarian Nordic make its next earnings announcement?

Bavarian Nordic is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Bavarian Nordic.

Who are some of Bavarian Nordic's key competitors?

How do I buy Bavarian Nordic stock?

Shares of Bavarian Nordic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bavarian Nordic's stock price today?

One share of Bavarian Nordic stock can currently be purchased for approximately $13.66.

How big of a company is Bavarian Nordic?

Bavarian Nordic has a market capitalization of $1.31 billion and generates $149.68 million in revenue each year. The company earns $4.54 million in net income (profit) each year or $0.74 on an earnings per share basis. Bavarian Nordic employs 437 workers across the globe.

How can I contact Bavarian Nordic?

Bavarian Nordic's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]


MarketBeat Community Rating for Bavarian Nordic (BVNRY)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Bavarian Nordic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bavarian Nordic (OTCMKTS:BVNRY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Bavarian Nordic (OTCMKTS:BVNRY) Consensus Price Target History

Price Target History for Bavarian Nordic (OTCMKTS:BVNRY)

Bavarian Nordic (OTCMKTS:BVNRY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/15/2017Maxim GroupDowngradeBuy -> HoldView Rating Details
10/19/2016CowenReiterated RatingBuyView Rating Details
9/19/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Bavarian Nordic (OTCMKTS:BVNRY) Earnings History and Estimates Chart

Earnings by Quarter for Bavarian Nordic (OTCMKTS:BVNRY)

Bavarian Nordic (OTCMKTS BVNRY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/8/2017Q3 2017$0.54$116.02 millionViewN/AView Earnings Details
8/25/2017Q2 2017$0.14$0.07$50.65 million$58.68 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.04($0.01)$37.88 million$28.33 millionViewN/AView Earnings Details
3/15/2017Q4 2016$0.17$0.14$86.48 million$60.23 millionViewN/AView Earnings Details
11/9/2016Q3 2016$0.16$67.80 millionViewN/AView Earnings Details
8/17/2016Q2 2016($0.05)$17.69 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.23)$3.33 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bavarian Nordic (OTCMKTS:BVNRY) Earnings Estimates

Current Year EPS Consensus Estimate: $0.5 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS

Dividends

Dividend History for Bavarian Nordic (OTCMKTS:BVNRY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bavarian Nordic (OTCMKTS BVNRY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Bavarian Nordic (OTCMKTS BVNRY) News Headlines

Source:
DateHeadline
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox VaccineBavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
feeds.benzinga.com - February 6 at 1:04 PM
Bavarian Nordic (BVNRY) Rating Lowered to Sell at ValuEngineBavarian Nordic (BVNRY) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - February 3 at 2:36 PM
Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer MetastasisBavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
feeds.benzinga.com - January 19 at 2:23 AM
Bavarian Nordic (BVNRY) Downgraded by Zacks Investment Research to "Sell"Bavarian Nordic (BVNRY) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 29 at 4:44 PM
Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox VaccineBavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
feeds.benzinga.com - November 21 at 1:40 PM
Bavarian Nordic (BVNRY) Lifted to "Hold" at Zacks Investment ResearchBavarian Nordic (BVNRY) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 20 at 5:32 PM
Bavarian Nordic A/S: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV VaccineBavarian Nordic A/S: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
www.finanznachrichten.de - November 9 at 6:17 PM
Bavarian Nordic (BVNRY) New Barda Contract For Freeze-Dried Imvamune - SlideshowBavarian Nordic (BVNRY) New Barda Contract For Freeze-Dried Imvamune - Slideshow
seekingalpha.com - September 29 at 3:58 PM
Bavarian Nordic nabs BARDA contract for smallpox vaccine valued up to $539MBavarian Nordic nabs BARDA contract for smallpox vaccine valued up to $539M
seekingalpha.com - September 29 at 8:33 AM
Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the US ... - GlobeNewswire (press release)Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the US ... - GlobeNewswire (press release)
globenewswire.com - September 27 at 10:45 PM
Bavarian Nordic Provides Update on its Universal RSV VaccineBavarian Nordic Provides Update on its Universal RSV Vaccine
www.nasdaq.com - September 21 at 11:24 AM
Cancer vaccines, long considered failures, are hot againCancer vaccines, long considered failures, are hot again
www.marketwatch.com - September 15 at 5:13 PM
Bavarian Nordic (BVNRY) Rating Lowered to Hold at Maxim GroupBavarian Nordic (BVNRY) Rating Lowered to Hold at Maxim Group
www.americanbankingnews.com - September 15 at 9:12 AM
Bavarian Nordic to Host Capital Markets Day in New York CityBavarian Nordic to Host Capital Markets Day in New York City
globenewswire.com - September 14 at 10:36 PM
Bavarian Nordic (BVNRY) Posts  Earnings ResultsBavarian Nordic (BVNRY) Posts Earnings Results
www.americanbankingnews.com - August 26 at 10:14 AM
Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc.Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc.
globenewswire.com - August 22 at 5:26 PM
Bavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.Bavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.
www.nasdaq.com - August 21 at 9:45 PM
Bavarian Nordic (BVNRY) to Release Quarterly Earnings on FridayBavarian Nordic (BVNRY) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - August 21 at 9:02 AM
Bavarian Nordic A/S: Bavarian Nordic Announces Subscription Price and Number of Shares to be Issued to Johnson & Johnson Innovation - JJDC, Inc.Bavarian Nordic A/S: Bavarian Nordic Announces Subscription Price and Number of Shares to be Issued to Johnson & Johnson Innovation - JJDC, Inc.
www.finanznachrichten.de - August 10 at 3:02 AM
Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.
globenewswire.com - July 27 at 3:55 AM
Bavarian Nordic Issues Warrants to Newly Appointed Member of the Executive ManagementBavarian Nordic Issues Warrants to Newly Appointed Member of the Executive Management
www.nasdaq.com - July 3 at 9:54 PM
Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV VaccineBavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
globenewswire.com - June 27 at 4:20 PM
Bavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramBavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
globenewswire.com - May 19 at 9:00 PM
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsBavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
globenewswire.com - May 18 at 4:02 PM
Bavarian Nordic: A Stock You Should Not Miss In 2017Bavarian Nordic: A Stock You Should Not Miss In 2017
seekingalpha.com - April 7 at 8:47 AM
Bavarian Nordic A/S - Notice Convening Ordinary General MeetingBavarian Nordic A/S - Notice Convening Ordinary General Meeting
globenewswire.com - April 3 at 9:29 PM
Bavarian Nordic Announces Annual Report 2016Bavarian Nordic Announces Annual Report 2016
www.nasdaq.com - March 15 at 4:25 PM
Therapy Focus - Against The Odds, Cancer Vaccines Plough OnTherapy Focus - Against The Odds, Cancer Vaccines Plough On
seekingalpha.com - February 28 at 1:48 PM
Bavarian Nordic A/S: Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT StudyBavarian Nordic A/S: Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study
www.finanznachrichten.de - January 5 at 4:31 PM
7:04 am Bavarian Nordic A/S initiates a clinical trial combining its cancer immunotherapy candidate CV301 with the anti-PD-1 drug Opdivo from Bristol-Myers Squibb (<a href="/q?s=bmy" name="bmy">BMY</a>)7:04 am Bavarian Nordic A/S initiates a clinical trial combining its cancer immunotherapy candidate CV301 with the anti-PD-1 drug Opdivo from Bristol-Myers Squibb (BMY)
us.rd.yahoo.com - December 29 at 9:28 PM

SEC Filings

Bavarian Nordic (OTCMKTS:BVNRY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Bavarian Nordic (OTCMKTS BVNRY) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.